Methods, dosing regimens and medications using anti-progestational agents for the treatment of disorders

Abstract

The present invention relates to the treatment of disorders using anti-progestational agents. More specifically, the present invention relates to the treatment of disorders using low doses of anti-progestational agents. Compared to dosages and lengths of treatment taught by the prior art, the described methods, dosing regimens and medications use effective dosages and lengths of treatment that are lower and/or shorter than previously thought possible.

1 - 66 . (canceled) 
     
     
         67 . A method for treating uterine fibroids or tumors deriving therefrom, which method comprises administering to a patient in need thereof, an effective amount of 17α-acetoxy-11β-[4-N,N-dimethylamino-phenyl)-19-norpregna-4,9-diene-3,20-dione (ulipristal). 
     
     
         68 . The method of claim  1 , wherein the patient is administered with a tablet comprising ulipristal. 
     
     
         69 . The method of claim  1 , wherein the patient is administered with a daily dosage of 5 to 15 mg ulipristal. 
     
     
         70 . The method of claim  3 , herein the patient is administered with a daily dosage of 10 mg ulipristal. 
     
     
         71 . The method of claim  1 , wherein the patient is administered with ulipristal. 
     
     
         72 . The method of claim  1 , wherein the patient is administered with an oral dosage of ulipristal during a period of about 2 to about 4 months. 
     
     
         73 . The method of claim  7 , which is repeated once a year. 
     
     
         74 . The method of claim  1 , wherein the patient is administered with ulipristal before undergoing surgery of the uterus. 
     
     
         75 . The method of claim  1 , whereby bleeding is reduced or stopped. 
     
     
         76 . A method for reducing or stopping bleeding in a patient afflicted with uterine fibroids, which method comprises administering to a patient in need thereof, an effective amount of 17α-acetoxy-11β-[4-N,N-dimethylamino-phenyl)-19-norprepa-4,9-diene-3,20-dione (ulipristal). 
     
     
         77 . A method for preventing or treating anemia in a patient afflicted with uterine fibroids, which method comprises administering to a patient in need thereof, an effective amount of 17α-acetoxy-11β-[4-N,N-dimethylamino-phenyl)-19-norpregna-4,9-diene-3,20-dione (ulipristal). 
     
     
         78 . A method for reducing the size of uterine fibroids, which method comprises administering to a patient in need thereof, an effective amount of 17α-acetoxy-11β-[4-N,N-dimethylamino-phenyl)-19-norpregna-4,9-diene-3,20-dione (ulipristal). 
     
     
         79 . A method for reducing uterine volume, which method comprises administering to a patient in need thereof, an effective amount of 17α-acetoxy-11β-[4-N,N dimethylamino-phenyl)-19-norpregna-4,9-diene-3,20-dione (ulipristal).